What good is working without a window to look out of? As I look out of mine (at my work-in-progress back garden), it’s good to see the early signs of Spring.
A similar optimism, I’m noticing, is getting around the pharmaceutical industry as players and stakeholders continue to band together in the aim of making lives around the world better, despite ongoing challenges such as COVID-19, and emerging challenges such as the Marburg outbreak being witnessed in Equatorial Guinea, for which the WHO has intensified its vigilance. Bird flu strains being found in other species will present another challenge, but these are the reasons why young researchers chose a profession in medicine; these are the challenges that drive them. These are the legacies they hope to leave to the new generations that follow. I’m looking forward to hearing more of the new ideas and approaches from young scientists and CEOs as the days begin to get warmer, brighter, and fresher.
New European Union (EU) Health Technology Assessment (HTA) regulation was enacted in January 2022 to help streamline the clinical assessment process for EU member states' HTA bodies. Read how manufacturers can navigate these changes effectively during clinical development & market access planning.
Breaches of code lead to APBI President resignation
Pinder Sahota, General Manager, Novo Nordisk UK, has stepped down as President of the ABPI over concerns that an ongoing process concerning Novo Nordisk breaches of the ABPI Code of Practice would distract from the ABPI’s work. ABPI Vice President Susan Rienow will temporarily assume responsibilities. Novo Nordisk was found to be in violation of the ABPI code recently, in addition to “multiple breaches” reported last year. Continue reading
Technology to take on brain cancer
A joint research project between Yale and the University of Connecticut has developed a nanoparticle-based treatment that targets multiple culprits in glioblastoma. Published in Science Advances, results show that the new treatment uses bioadhesive nanoparticles that adhere to the site of the tumor before releasing synthesized peptide nucleic acids, which target the overexpressed microRNAs “oncomiRs” that cause the proliferation of cancer cells and tumor growth. The researchers are seeking to improve therapeutic approaches for targeting the molecular genetic mediators of glioblastoma. Continue reading
Also in the News...
Gavi approves appointment of Muhammad Ali Pate as CEO; Seth Barkley to step down in August after 12 years as the Vaccine Alliance chief.
FDA grants full approval for GSK’s Jemperli for adults with recurrent or advanced mismatch repair-deficient endometrial cancer.
Takeda announces acquisition of all shares of Nimbus Lakshmi from Nimbus Therapeutics, following clearance from US FTC.
Catalent completes $2.2 million expansion to clinical supply facility in Singapore. The CDMO will install 35 freezers for storage for the support of advanced modalities, including mRNA-based vaccines.
FDA grants pediatric approval of Regeneron’s EYLEA (aflibercept) injection to treat preterm infants with retinopathy of prematurity. EYLEA is now indicated to treat five retinal conditions.
More From The Medicine Maker
Welcome to the CRISPR Powerhouse
Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.Read the article
Weathering the Storm: Cell and Gene’s Economic Downturn
An early wave of investor enthusiasm followed by an economic crisis has landed our field in a sea of trouble – so how can we swim to shore?Read the article
The Medicine Maker Company of the Year Awards 2022
Welcome to The Medicine Maker’s inaugural Company of the Year Awards! Here, we celebrate six victorious companies contributing to drug development and manufacture across six categories.Read the article
On-Demand Digital Events
To Freeze or not to freeze - challenges and innovations in cell therapy logistics Available On-Demand
Video Discussion: The Growing Importance of Sustainability in Pharma Available On-Demand
Fiber-based chromatography to improve productivity in downstream AAV processing Available On-Demand
SPONSORED / MARKETPLACE
Video Interview: Gian Connor of Corning on Packaging We speak with Gian Connor from Corning about the evolution of the pharmaceutical packaging industry and Corning’s Velocity vials. Watch the video
Niek Stapel on Talent, Trends, and Quality Check out this video interview with Veranova CEO Niek Stapel, covering industry trends and how the company is evolving. Watch the video
SPONSORED / PODCAST
Form and Content Ep 2 - Injection
Tobias Rosenkrantz talks us through his work on high concentration protein therapeutics, and what the solutions he has come up with could mean for patients and their medicines.
Pharmaceutical Professionals (from the Medicine Maker) Join our informative and vibrant LinkedIn Group now. Set up exclusively for our valued community of medicine makers to discuss the latest industry content. Join us on LinkedIn!
Free Ebook: Pharmaceutical Technology and Innovation
Catch up on new technology releases; read thoughts and views on the true meaning of innovation; and learn about key technology trends that could transform the field.
Throughout 2022, we posed a series of questions to great minds working in the cell and gene field. Here, we share some of the most thought provoking answers.
Introducing ID Transmission! ID Transmission explores humanity’s ongoing battle against infectious diseases. Find out more by visiting the brand new website!
THE INNOVATION AWARDS 2023
Vote for the Grand Winner of the Innovation Awards!
Last year, we asked you to nominate the best new releases in drug development and manufacturing technology. Now, it’s time to vote for the Grand Winner. Vote now!
